CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, a privately-held pharmaceutical company focused on disease-modifying treatments for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases, today announced the election of Nobel Laureate and former Biogen CEO Walter Gilbert, PhD, to the company’s board of directors.
